News
ABT
107.81
-0.14%
-0.15
3 Inflation Resilient Dividend Stocks Offering Steady Income as CPI and Rate Risks Loom
Simply Wall St · 19h ago
HQH: After Biotech's Breakout Year, This Healthcare CEF Still Trades Below NAV; Buy
Seeking Alpha · 1d ago
AbbVie vs. Abbott Laboratories: Which Healthcare Stock Is a Better Buy in 2026?
The Motley Fool · 1d ago
NVST vs. ABT: Which Stock Is the Better Value Option?
NASDAQ · 1d ago
Medical devices ETF nears breakout; here are its top holdings
Seeking Alpha · 1d ago
Vanguard High Dividend Yield ETF Experiences Big Inflow
NASDAQ · 1d ago
Abbott (ABT) Stock Trades At A Cash Flow Discount But An Earnings Premium
Simply Wall St · 1d ago
Abbott Laboratories Takes Over #58 Spot From PPL
NASDAQ · 2d ago
S&P 500 Analyst Moves: ABT
NASDAQ · 2d ago
Boston Scientific's 2026 Guidance Cut Puts Its Recovery to the Test
NASDAQ · 2d ago
Abbott Stock: Is Wall Street Bullish or Bearish?
Barchart · 2d ago
DexCom Inc. Stock Sheds 4.9%, Underperforms Market
Dow Jones · 3d ago
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT), Lemaitre Vascular (LMAT) and Harmony Biosciences Holdings (HRMY)
TipRanks · 3d ago
SCHD, BEX: Big ETF Inflows
NASDAQ · 4d ago
Matrix Asset Advisors' Large Cap Value Portfolio adds ABT and MCD; exits NSRGY
Seeking Alpha · 5d ago
Weekly Report: what happened at ABT last week (0727-0731)?
Weekly Report · 5d ago
Here’s Why These 3 ETFs Are Beating the S&P 500 Index in 2026
TipRanks · 6d ago
Abbott Laboratories vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026?
The Motley Fool · 6d ago
DexCom Inc. Stock Rises 12.0%, Outperforms Peers
Dow Jones · 07/31 20:33
Abbott Laboratories vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
The Motley Fool · 07/31 19:49
More
Webull provides a variety of real-time ABT stock news. You can receive the latest news about Abbott Labs through multiple platforms. This information may help you make smarter investment decisions.
About ABT
Abbott Laboratories is a global healthcare company. The Company’s principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. Its segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. Diagnostic Products segment is involved in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. Nutritional Products segment is engaged in the worldwide sales of a broad line of adult and pediatric nutritional products. Medical Devices segment is involved in the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. It serves people in more than 160 countries.